Evidence map›Paper›PMID 24424270›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2014

Tunable sustained intravitreal drug delivery system for daunorubicin using oxidized porous silicon.

Huiyuan Hou, Alejandra Nieto, Feiyan Ma, William R Freeman, Michael J Sailor, Lingyun Cheng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 0 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Micelle formulation of hexadecyloxypropyl-cidofovir (HDP-CDV) as an intravitreal long-lasting delivery system.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2015
    Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Huiyuan HouDepartment of Ophthalmology, Jacobs Retina Center at Shiley Eye Center, University of California San Diego, La Jolla, USA; Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, USA.
Alejandra NietoDepartment of Ophthalmology, Jacobs Retina Center at Shiley Eye Center, University of California San Diego, La Jolla, USA; Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, USA.
Feiyan MaDepartment of Ophthalmology, Jacobs Retina Center at Shiley Eye Center, University of California San Diego, La Jolla, USA.
William R FreemanDepartment of Ophthalmology, Jacobs Retina Center at Shiley Eye Center, University of California San Diego, La Jolla, USA.
Michael J SailorDepartment of Chemistry and Biochemistry, University of California San Diego, La Jolla, USA.
Lingyun ChengDepartment of Ophthalmology, Jacobs Retina Center at Shiley Eye Center, University of California San Diego, La Jolla, USA. Electronic address: cheng@eyecenter.ucsd.edu.
University of California San Diego · USEye Center · SA

Funding

Vision BiostatisticsP30EY022589 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Derek Stuart Welsbie · 2012 to 2026
$10.3M
Porous Silicon Particles for Sustained Intravitreal Drug DeliveryR01EY020617 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHENG, LINGYUN · 2011 to 2015
$2.6M
NEI NIH HHS EY020617NEI NIH HHS P30 EY022589NEI NIH HHS R01 EY020617
6 · The paper itself

Abstract

Daunorubicin (DNR) is an effective inhibitor of an array of proteins involved in neovascularization, including VEGF and PDGF. These growth factors are directly related to retina scar formation in many devastating retinal diseases. Due to the short vitreous half-life and narrow therapeutic window, ocular application of DNR is limited. It has been shown that a porous silicon (pSi) based delivery system can extend DNR vitreous residence from a few days to 3months. In this study we investigated the feasibility of altering the pore size of the silicon particles to regulate the payload release. Modulation of the etching parameters allowed control of the nano-pore size from 15nm to 95nm. In vitro studies showed that degradation of pSiO2 increased with increasing pore size and the degradation of pSiO2 was approximately constant for a given particle type. The degradation of pSiO2 with 43nm pores was significantly greater than the other two particles with smaller pores, judged by observed and normalized mean Si concentration of the dissolution samples (44.2±8.9 vs 25.7±5.6 or 21.2±4.2μg/mL, p<0.0001). In vitro dynamic DNR release revealed that pSiO2-CO2H:DNR (porous silicon dioxide with covalent loading of daunorubicin) with large pores (43nm) yielded a significantly higher DNR level than particles with 15 or 26nm pores (13.5±6.9ng/mL vs. 2.3±1.6ng/mL and 1.1±0.9ng/mL, p<0.0001). After two months of in vitro dynamic release, 54% of the pSiO2-CO2H:DNR particles still remained in the dissolution chamber by weight. In vivo drug release study demonstrated that free DNR in the vitreous at post-injection day 14 was 66.52ng/mL for 95nm pore size pSiO2-CO2H:DNR, 10.76ng/mL for 43nm pSiO2-CO2H:DNR, and only 1.05ng/mL for 15nm pSiO2-CO2H:DNR. Pore expansion from 15nm to 95nm led to a 63 fold increase of DNR release (p<0.0001) and a direct correlation between the pore size and the drug levels in the living eye vitreous was confirmed. The present study demonstrates the feasibility of regulating DNR release from pSiO2 covalently loaded with DNR by engineering the nano-pore size of pSi.

Indexed as

Drug Delivery SystemsAnimalsAntibiotics, AntineoplasticCell LineCell ProliferationDaunorubicinDelayed-Action PreparationsHumansIntravitreal InjectionsOxidation-ReductionPorosityRabbitsSiliconVitreous BodyAntibiotics, AntineoplasticDaunorubicinDelayed-Action PreparationsSilicon3-AminopropyltriethoxysilaneControlled drug releaseDaunorubicinDaunorubicin hydrochlorideEthanolHydrofluoric acidIntravitreal drug deliveryN-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochlorideNitrogenN,N-dimethylformamidePorous siliconRabbit eyeSiliconSilicon dioxideSuccinic anhydride

Identifiers

PMID24424270
PMCPMC3951847
OpenAlexW818694610

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.